Annual EBIT
$9.98 B
+$2.00 B+25.08%
31 December 2023
Summary:
Novartis AG annual earnings before interest & taxes is currently $9.98 billion, with the most recent change of +$2.00 billion (+25.08%) on 31 December 2023. During the last 3 years, it has fallen by -$769.00 million (-7.16%). NVS annual EBIT is now -60.59% below its all-time high of $30.91 billion.NVS EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
$3.65 B
-$438.00 M-10.72%
30 September 2024
Summary:
Novartis AG quarterly earnings before interest & taxes is currently $3.65 billion, with the most recent change of -$438.00 million (-10.72%) on 30 September 2024. Over the past year, it has increased by +$1.88 billion (+105.69%). NVS quarterly EBIT is now -76.50% below its all-time high of $15.53 billion, reached on 31 December 2021.NVS Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
$13.68 B
+$1.88 B+15.88%
30 September 2024
Summary:
Novartis AG TTM earnings before interest & taxes is currently $13.68 billion, with the most recent change of +$1.88 billion (+15.88%) on 30 September 2024. Over the past year, it has increased by +$4.52 billion (+49.34%). NVS TTM EBIT is now -46.43% below its all-time high of $25.54 billion, reached on 31 March 2022.NVS TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NVS EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +25.1% | +105.7% | +49.3% |
| 3 y3 years | -7.2% | +6.3% | +9.0% |
| 5 y5 years | -33.6% | +39.1% | +45.4% |
NVS EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -60.6% | +25.1% | -76.5% | +105.7% | -46.4% | +60.3% |
| 5 y | 5 years | -60.6% | +25.1% | -76.5% | +105.7% | -46.4% | +60.3% |
| alltime | all time | -60.6% | +116.4% | -76.5% | +133.2% | -46.4% | +884.0% |
Novartis AG EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $3.65 B(-10.7%) | $13.68 B(+15.9%) |
| June 2024 | - | $4.09 B(+22.0%) | $11.80 B(+11.3%) |
| Mar 2024 | - | $3.35 B(+29.1%) | $10.61 B(+6.3%) |
| Dec 2023 | $9.98 B(+25.1%) | $2.59 B(+46.2%) | $9.98 B(+8.9%) |
| Sept 2023 | - | $1.77 B(-38.6%) | $9.16 B(-0.2%) |
| June 2023 | - | $2.89 B(+6.3%) | $9.18 B(+7.6%) |
| Mar 2023 | - | $2.72 B(+53.2%) | $8.53 B(-1.7%) |
| Dec 2022 | $7.98 B(-68.5%) | $1.78 B(-0.9%) | $8.68 B(-61.3%) |
| Sept 2022 | - | $1.79 B(-20.1%) | $22.43 B(-6.8%) |
| June 2022 | - | $2.24 B(-21.8%) | $24.07 B(-5.7%) |
| Mar 2022 | - | $2.87 B(-81.5%) | $25.54 B(+0.9%) |
| Dec 2021 | $25.32 B(+135.6%) | $15.53 B(+352.4%) | $25.32 B(+101.7%) |
| Sept 2021 | - | $3.43 B(-7.4%) | $12.55 B(+6.9%) |
| June 2021 | - | $3.71 B(+39.8%) | $11.74 B(+11.4%) |
| Mar 2021 | - | $2.65 B(-3.9%) | $10.54 B(-1.9%) |
| Dec 2020 | $10.75 B(+9.8%) | $2.76 B(+5.4%) | $10.75 B(+8.0%) |
| Sept 2020 | - | $2.62 B(+4.4%) | $9.95 B(-0.0%) |
| June 2020 | - | $2.51 B(-12.3%) | $9.95 B(-3.2%) |
| Mar 2020 | - | $2.86 B(+45.8%) | $10.28 B(+5.0%) |
| Dec 2019 | $9.79 B(-34.9%) | $1.96 B(-25.2%) | $9.79 B(+4.0%) |
| Sept 2019 | - | $2.62 B(-7.6%) | $9.41 B(+1.5%) |
| June 2019 | - | $2.84 B(+20.0%) | $9.27 B(-37.5%) |
| Mar 2019 | - | $2.37 B(+49.7%) | $14.84 B(-1.3%) |
| Dec 2018 | $15.03 B(+52.5%) | $1.58 B(-36.3%) | $15.03 B(-6.3%) |
| Sept 2018 | - | $2.48 B(-70.5%) | $16.03 B(-0.9%) |
| June 2018 | - | $8.41 B(+228.7%) | $16.18 B(+57.4%) |
| Mar 2018 | - | $2.56 B(-1.0%) | $10.28 B(+4.4%) |
| Dec 2017 | $9.85 B(+15.6%) | $2.58 B(-1.8%) | $9.85 B(+15.7%) |
| Sept 2017 | - | $2.63 B(+5.0%) | $8.51 B(+2.2%) |
| June 2017 | - | $2.51 B(+17.9%) | $8.33 B(+2.6%) |
| Mar 2017 | - | $2.13 B(+70.7%) | $8.11 B(-4.8%) |
| Dec 2016 | $8.52 B(-3.0%) | $1.25 B(-49.1%) | $8.52 B(-0.5%) |
| Sept 2016 | - | $2.45 B(+6.8%) | $8.57 B(+1.5%) |
| June 2016 | - | $2.29 B(-9.6%) | $8.44 B(-0.3%) |
| Mar 2016 | - | $2.54 B(+96.8%) | $8.47 B(-3.6%) |
| Dec 2015 | $8.79 B(-32.3%) | $1.29 B(-44.5%) | $8.79 B(-15.8%) |
| Sept 2015 | - | $2.32 B(+0.1%) | $10.44 B(-11.8%) |
| June 2015 | - | $2.32 B(-18.8%) | $11.84 B(-7.7%) |
| Mar 2015 | - | $2.86 B(-3.0%) | $12.83 B(-1.1%) |
| Dec 2014 | $12.98 B(+12.9%) | $2.94 B(-20.7%) | $12.98 B(+4.0%) |
| Sept 2014 | - | $3.71 B(+12.1%) | $12.48 B(+9.2%) |
| June 2014 | - | $3.31 B(+10.2%) | $11.42 B(+0.9%) |
| Mar 2014 | - | $3.00 B(+22.9%) | $11.32 B(-0.1%) |
| Dec 2013 | $11.49 B(-3.9%) | $2.45 B(-8.0%) | $11.33 B(-3.5%) |
| Sept 2013 | - | $2.66 B(-17.2%) | $11.74 B(-2.5%) |
| June 2013 | - | $3.21 B(+6.5%) | $12.04 B(-0.9%) |
| Mar 2013 | - | $3.01 B(+5.4%) | $12.15 B(+1.6%) |
| Dec 2012 | $11.96 B | $2.86 B(-3.3%) | $11.96 B(+15.9%) |
| Sept 2012 | - | $2.96 B(-10.8%) | $10.32 B(-1.4%) |
| June 2012 | - | $3.32 B(+17.5%) | $10.46 B(-1.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | $2.82 B(+132.0%) | $10.58 B(-6.4%) |
| Dec 2011 | $11.31 B(-8.8%) | $1.22 B(-60.8%) | $11.31 B(-11.0%) |
| Sept 2011 | - | $3.11 B(-9.6%) | $12.71 B(+1.0%) |
| June 2011 | - | $3.44 B(-3.1%) | $12.58 B(+2.5%) |
| Mar 2011 | - | $3.55 B(+35.6%) | $12.28 B(-0.9%) |
| Dec 2010 | $12.39 B(+18.3%) | $2.62 B(-12.3%) | $12.39 B(-1.8%) |
| Sept 2010 | - | $2.98 B(-4.8%) | $12.63 B(+2.6%) |
| June 2010 | - | $3.13 B(-14.5%) | $12.31 B(+4.7%) |
| Mar 2010 | - | $3.66 B(+28.6%) | $11.75 B(+12.2%) |
| Dec 2009 | $10.47 B(+7.0%) | $2.85 B(+6.9%) | $10.47 B(+10.7%) |
| Sept 2009 | - | $2.66 B(+3.3%) | $9.46 B(+1.6%) |
| June 2009 | - | $2.58 B(+8.3%) | $9.31 B(-0.9%) |
| Mar 2009 | - | $2.38 B(+29.8%) | $9.40 B(-1.1%) |
| Dec 2008 | $9.79 B(+26.7%) | $1.83 B(-27.1%) | $9.50 B(+6.6%) |
| Sept 2008 | - | $2.52 B(-5.6%) | $8.92 B(+5.6%) |
| June 2008 | - | $2.67 B(+7.1%) | $8.45 B(+7.9%) |
| Mar 2008 | - | $2.49 B(+99.0%) | $7.83 B(+2.0%) |
| Dec 2007 | $7.72 B(-6.5%) | $1.25 B(-38.8%) | $7.67 B(-12.5%) |
| Sept 2007 | - | $2.04 B(-0.1%) | $8.77 B(+0.7%) |
| June 2007 | - | $2.04 B(-12.4%) | $8.70 B(-0.2%) |
| Mar 2007 | - | $2.33 B(-0.3%) | $8.72 B(+3.3%) |
| Dec 2006 | $8.26 B(+15.3%) | $2.34 B(+18.4%) | $8.45 B(+7.6%) |
| Sept 2006 | - | $1.98 B(-4.2%) | $7.85 B(+1.2%) |
| June 2006 | - | $2.06 B(+0.3%) | $7.75 B(+2.9%) |
| Mar 2006 | - | $2.06 B(+18.0%) | $7.54 B(+5.3%) |
| Dec 2005 | $7.16 B(+7.3%) | $1.74 B(-7.6%) | $7.16 B(+1.1%) |
| Sept 2005 | - | $1.89 B(+2.1%) | $7.08 B(+2.5%) |
| June 2005 | - | $1.85 B(+10.1%) | $6.91 B(+0.8%) |
| Mar 2005 | - | $1.68 B(+0.8%) | $6.86 B(+2.8%) |
| Dec 2004 | $6.67 B(+11.6%) | $1.67 B(-3.0%) | $6.67 B(-0.4%) |
| Sept 2004 | - | $1.72 B(-4.3%) | $6.70 B(+3.8%) |
| June 2004 | - | $1.79 B(+20.1%) | $6.45 B(+5.4%) |
| Mar 2004 | - | $1.49 B(-11.8%) | $6.12 B(+2.4%) |
| Dec 2003 | $5.98 B(+1.4%) | $1.69 B(+15.3%) | $5.98 B(-7.0%) |
| Sept 2003 | - | $1.47 B(+0.4%) | $6.43 B(+3.7%) |
| June 2003 | - | $1.46 B(+8.3%) | $6.20 B(+0.3%) |
| Mar 2003 | - | $1.35 B(-37.0%) | $6.18 B(-36.2%) |
| Dec 2002 | $5.89 B(+20.0%) | $2.15 B(+72.8%) | $9.69 B(-655.2%) |
| Sept 2002 | - | $1.24 B(-13.9%) | -$1.75 B(-167.4%) |
| June 2002 | - | $1.44 B(-70.3%) | $2.59 B(+22.2%) |
| Mar 2002 | - | $4.86 B(-152.3%) | $2.12 B(+24.6%) |
| Dec 2001 | $4.91 B(+0.5%) | -$9.29 B(-266.6%) | $1.70 B(>+9900.0%) |
| Sept 2001 | - | $5.58 B(+474.3%) | $0.00(-100.0%) |
| June 2001 | - | $971.00 M(-78.1%) | -$695.00 M(+4.4%) |
| Mar 2001 | - | $4.44 B(-140.4%) | -$666.00 M(-212.7%) |
| Dec 2000 | $4.88 B(+5.9%) | -$10.99 B(-325.1%) | $591.00 M(-94.9%) |
| Sept 2000 | - | $4.88 B(+388.1%) | $11.58 B(+72.9%) |
| June 2000 | - | $1.00 B(-82.4%) | $6.70 B(+17.6%) |
| Mar 2000 | - | $5.70 B | $5.70 B |
| Dec 1999 | $4.61 B(-8.3%) | - | - |
| Dec 1998 | $5.03 B | - | - |
FAQ
- What is Novartis AG annual earnings before interest & taxes?
- What is the all time high annual EBIT for Novartis AG?
- What is Novartis AG annual EBIT year-on-year change?
- What is Novartis AG quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Novartis AG?
- What is Novartis AG quarterly EBIT year-on-year change?
- What is Novartis AG TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Novartis AG?
- What is Novartis AG TTM EBIT year-on-year change?
What is Novartis AG annual earnings before interest & taxes?
The current annual EBIT of NVS is $9.98 B
What is the all time high annual EBIT for Novartis AG?
Novartis AG all-time high annual earnings before interest & taxes is $30.91 B
What is Novartis AG annual EBIT year-on-year change?
Over the past year, NVS annual earnings before interest & taxes has changed by +$2.00 B (+25.08%)
What is Novartis AG quarterly earnings before interest & taxes?
The current quarterly EBIT of NVS is $3.65 B
What is the all time high quarterly EBIT for Novartis AG?
Novartis AG all-time high quarterly earnings before interest & taxes is $15.53 B
What is Novartis AG quarterly EBIT year-on-year change?
Over the past year, NVS quarterly earnings before interest & taxes has changed by +$1.88 B (+105.69%)
What is Novartis AG TTM earnings before interest & taxes?
The current TTM EBIT of NVS is $13.68 B
What is the all time high TTM EBIT for Novartis AG?
Novartis AG all-time high TTM earnings before interest & taxes is $25.54 B
What is Novartis AG TTM EBIT year-on-year change?
Over the past year, NVS TTM earnings before interest & taxes has changed by +$4.52 B (+49.34%)